ArticleAndrology2025
Effects of AZFc (b2/b4, b1/b3, b2/b3, and gr/gr) deletions and primary duplications on the outcomes of the first intracytoplasmic sperm injection treatment cycle: A single-center retrospective cohort study.
Article in Andrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCurrent advances in high-throughput sequencing technology enable the precise identification of Y chromosome microdeletion and primary duplication in infertile couples, but the mechanism and clinical significance of these mutations in assisted reproductive techniques remain unclear.
objectivesTo investigate the effects of AZFc (b2/b4, b1/b3, b2/b3, and gr/gr) deletions and primary duplications on the outcomes of the first intracytoplasmic sperm injection (ICSI) treatment cycle.
methodsY chromosome microdeletions and primary duplications in infertile men were detected using next-generation sequencing (NGS) technology. A total of 813 patients undergoing their first ICSI treatment were divided into six groups: b2/b4 deletion group (n = 28), three partial AZFc subdeletion groups (b1/b3, n = 13; b2/b3, n = 72; gr/gr, n = 71), primary AZFc duplication group (n = 54), and control group with a normal Y chromosome (n = 575). The multivariate logistic regression analyses were conducted to assess and compare the embryologic and cumulative reproductive outcomes of ICSI treatment across these groups.
resultsCompared with the control group, the b2/b4 deletion group showed a poor ICSI embryologic outcome after ICSI treatment, with a significantly lower fertilization rate per oocytes retrieval (72.22% vs.79.89%; adjusted odds ratio [OR], 0.63; 95% confidence interval [CI], 0.45-0.88, p < 0.01) and 2 pronuclear (2PN) fertilization rate (66.37% vs. 74.80%; adjusted OR, 0.65; 95% CI, 0.47-0.89, p < 0.01) either before or after adjustment for confounding factors. Nevertheless, three partial AZFc deletion groups showed no effect on the ICSI fertilization rate after ICSI treatment. The primary AZFc duplication group had a significantly lower clinical pregnancy rate per transferred embryo (56.25% vs. 65.97%; adjusted OR, 0.64; 95% CI, 0.41-0.99, p < 0.05), and the semen characteristics varied from azoospermia to normozoospermia. In addition, all indicators related to embryo quality, clinical pregnancy, and live birth outcomes in the primary duplication group were inferior to those in the control group.
conclusionThis study indicates that b2/b4 deletion has a negative effect on ICSI outcomes, particularly the fertilization rates. Partial AZFc deletions have no significant effect on the fertilization rate after ICSI treatment. Primary AZFc duplication can lead to varying seminal phenotypes and has a negative effect on ICSI embryologic and pregnancy outcomes, particularly showing a significant association with low birth weight in newborns after ICSI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.